Business
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI).Managing blood pressure instability is a major unmet need after SCI, with a significant impac
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CPLGUw1yVOurWsVIgzW3oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"text","content":"THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)","length":132,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI).","length":274,"tagName":"p"}]},{"val":[{"type":"text","content":"Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate.","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":555,"olType":false},{"type":"text","content":"EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI.","length":626,"tagName":"p"},{"type":"text","content":"Empower BP is the Company’s second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, do...